~~<i id='5DC6525BC9'><strike id='5DC6525BC9'><tt id='5DC6525BC9'><pre id='5DC6525BC9'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

Wikipedia

author：Wikipedia 2025-10-01 17:42:35 - browse：49965

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： United colonoscopy coverage change 'may cost lives,' doctors say
Next article： Would Medicare drug price negotiations stall in a shutdown?

focus

hotspot

entertainment

leisure time

explore

AdobeShouldwepitythe“poorhistorians”—theindividualsorfamilymemberswhocan’tgiveaclearaccountingofthei

WSS

Menendez indictment could see pharma lose a key ally

Readers respond to H5N1 and livestock movements, and more

Health tech startups drop sharply from 2021 highs

Case highlights the risks of experimental stem cell therapy

Readers respond to H5N1 and livestock movements, and more

Inequities make cancer less preventable for women: report

focus

Wikipedia

focus

23andMe had bad news about my health. I wish a person had delivered it

Biogen shutters digital health group, ends Apple study, in cost cutting move

Moonlake's readout produced a cash windfall. Risks remain

Venture capitalist Bob Kocher on the state of digital health

In age of alternative facts, a scholarly course on calling out crap

Criminal prosecution for violating HIPAA: an emerging threat

Medicare details structure of new drug price negotiation program

Biogen shutters digital health group, ends Apple study, in cost cutting move

How one medical school became remarkably diverse

Readers respond to H5N1 and livestock movements, and more

hotspot

Microsoft's Peter Lee says ChatGPT shouldn't be used for initial diagnosis

Glen Campbell's doctor discusses his public struggle with Alzheimer's

Mindstrong's demise and the future of mental health care

Intercept Pharmaceuticals sells itself for less than $1 billion

Helping hospitals and community health centers plan for resilience

NVIDIA and Google execs on the future of AI and drug discovery

entertainment

leisure time

leisure time

explore